TC
IGMS

Telemus Capital’s IGM Biosciences IGMS Stock Holding History

Telemus Capital’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,000
Closed -$751K – 405
2020
Q3 		$751K Buy
10,000
+5,000
+100% +$296K 0.06% 238
2020
Q2 		$354K Buy
5,000
+1,000
+25% +$60.8K 0.03% 320
2020
Q1 		$259K Buy
+4,000
New +$175K 0.02% 327

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Telemus Capital's IGMS Position: Q4 2020 in Review

Telemus Capital sold out of IGM Biosciences (IGMS) in Q4 2020, closing a stake of 10,000 shares — an estimated $751K sold.

Telemus Capital first reported a position in IGMS in Q1 2020 and held it in 3 quarters. The position peaked at $751K in Q3 2020. 107 funds tracked by Wall St. Rank hold IGMS as of Q4 2020.

  • Telemus Capital reported no remaining IGM Biosciences position as of Q4 2020 after selling out during the quarter.
  • Telemus Capital sold 10,000 IGM Biosciences shares in Q4 2020, an estimated $751K.
  • Telemus Capital first reported a position in IGM Biosciences in Q1 2020 and held it in 3 quarters.
  • Telemus Capital's IGM Biosciences position peaked at $751K in Q3 2020.
  • 107 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2020.

Based on Telemus Capital's 13F filing for Q4 2020, filed 28 Jan 2021.